Mike Atkins describes the results of this phase 2 study, which helps shed light on the role of ipilimumab and nivolumab in renal cancer.
Mike Atkins describes the results of this phase 2 study, which helps shed light on the role of ipilimumab and nivolumab in renal cancer.